Vimian Group AB (publ) (VIMIAN.ST)
SEK 42.2
(2.93%)
SEK 42.2
(2.93%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 310.31 Million EUR | 43.57% |
| 2022 | 216.14 Million EUR | 26.86% |
| 2021 | 170.38 Million EUR | 124.06% |
| 2020 | 76.04 Million EUR | 463.34% |
| 2019 | 13.49 Million EUR | 118.78% |
| 2018 | 6.17 Million EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 240.11 Million EUR | 41.46% |
| 2024 Q2 | 178.61 Million EUR | -43.65% |
| 2024 Q1 | 309.14 Million EUR | -0.27% |
| 2023 FY | 310.31 Million EUR | 43.57% |
| 2023 Q3 | 333.7 Million EUR | -0.43% |
| 2023 Q4 | 310.31 Million EUR | -7.01% |
| 2023 Q2 | 335.15 Million EUR | 43.07% |
| 2023 Q1 | 234.27 Million EUR | 8.39% |
| 2022 Q4 | 216.14 Million EUR | -26.58% |
| 2022 FY | 216.14 Million EUR | 26.86% |
| 2022 Q3 | 294.39 Million EUR | -5.85% |
| 2022 Q2 | 312.66 Million EUR | 5.96% |
| 2022 Q1 | 295.07 Million EUR | 73.18% |
| 2021 Q2 | 125.76 Million EUR | 67.39% |
| 2021 Q4 | 170.38 Million EUR | 34.38% |
| 2021 Q3 | 126.79 Million EUR | 0.82% |
| 2021 FY | 170.38 Million EUR | 124.06% |
| 2021 Q1 | 75.13 Million EUR | -1.2% |
| 2020 FY | 76.04 Million EUR | 463.34% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q4 | 76.04 Million EUR | 0.0% |
| 2019 FY | 13.49 Million EUR | 118.78% |
| 2018 FY | 6.17 Million EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AroCell AB (publ) | - SEK | -Infinity% |
| Devyser Diagnostics AB (publ) | 600 Thousand SEK | -51618.5% |
| Immunovia AB (publ) | 1.78 Million SEK | -17264.913% |
| Prostatype Genomics AB (publ) | 67 Thousand SEK | -463050.746% |
| SenzaGen AB | 1.67 Million SEK | -18448.177% |
| Spermosens AB | 230 Thousand SEK | -134817.826% |